The purpose of the study was to assess consensus and interobserver agreement among an inter- 
| I N T R O D U C T I O N
Concern has been repeatedly expressed regarding the accurate diagnosis of polycythemia vera (PV), particularly in its earlier stages. [1] [2] [3] The diagnostic thresholds for this diagnosis are those proposed by the World Health Organization (WHO), principally based on hemoglobin (Hb) values 4, 5 and those of the British Committee for Standards in Haematology (BCSH) that are predominantly based on hematocrit (Hct) levels. 6, 7 Ample discussion has followed on which of the two diagnostic approaches had the highest sensitivity for a diagnosis of early PV. 8, 9 More recent evidence has shown that the original 2008 WHO thresholds for Hb were too high and thus not sensitive enough in diagnosing early phase PV and poorly correlated with red cell mass study.
Because of these data and similar observational experience, it became evident that a group of JAK2-mutated patients with PV may present at onset with a subnormal serum erythropoietin (EPO) level, and Hb values <18.5 g/dL in males (range 16.0-18.4) and <16. the fraction of mPV patients decreased from 35% to 15%. 13, 14 Following proposals of experts, 15 a Hb level of 16.5 g/dL in men and 16.0 g/dL for women or a Hct level of 49% in men and 48% in women was determined to be the optimal cutoff levels for distinguishing JAK2-mutated ET from mPV 13 and recently adopted by the 2016 revised WHO classification. 5 In this regard, correct diagnosis of mPV constitutes an important issue and will certainly improve clinical management of patients while avoiding undertreatment and prevention of thrombotic events. 9, 15 Given the importance which is now given to an accurate histologic diagnosis of PV for purpose of identifying mPV, 2, 3 we conducted an international consensus study aimed to examine the interobserver diagnostic reproducibility. To this aim, we assessed the concordance achieved among a panel of six hematopathologists in identifying cases of mPV by BM morphology by separating them from cases of overt PV, ET, and controls.
| MATERIAL AND M ETHODS

| Study design and performance
The current work is the result of a collaborative project by the European LeukemiaNet (ELN) with international experts' participation. This manuscript was developed through extensive discussions that took place during two meetings in Frankfurt and Amsterdam, respectively. Table 2 . A few specimens, particularly of mPV displayed a minor degree of reticulin fibrosis ( Figure 1C) , and a small amount of stainable iron deposits were detectable in few samples. The other 19 samples included cases of ET and reactive marrows which were also classified correctly.
Discrimination of PV cases from ET ( Figure 1D ) was performed with complete consensus between the panelists according to the key morphological features (Table 1) as was distinction between PV and reactive BM changes (reactive polycythemia and reactive thrombocytosis), MDS and prefibrotic/early PMF (pre-PMF) which were also included among the controls.
In contrast with the PV specimens where a concordance rate of 95% (75/79) was observed, samples of the control group were more difficult to classify, with an unclear discrimination in two cases: one case with a differential diagnosis of mPV versus ET; the second case differential was mPV versus early stage PMF presenting with increased erythropoiesis. In all patients, the presence of increased hematopoietic cellularity was regarded as critical for the histological diagnosis of mPV.
Concerning overall agreement among the six hematopathologists results of concordance of the blinded microscopic assessment during the review Table 3 . Noteworthy was that more than a 90% agreement could be achieved among the six panelists. Kappa statistics of above 0.8 were in line with the almost perfect agreement among the panelists (Table 3) . Altogether, histological BM features of mPV were found to be identical to overt PV. and early phase disease including the so called mPV. 3, 12 PV patients with early stage disease represent a group which were not "captured" by the formerly used cutoffs for Hb and/or Hct. 15 A proportion of these patients may be wrongly diagnosed as ET or MPN-U. In our study, the existence of this early group is clearly demonstrated by the 24 patients derived from the New York (Weill-Cornell) series originally published by Silver and coworkers 3 who did not meet the 2008 WHO criteria 4 for an increased Hb, but were diagnosed as PV based on the presence of an elevated Cr-51 RCM, mostly subnormal EPO level, and BM histology that was characteristic of PV. 3, 9, 12, 19 Although considered as a "diagnostic gold standard" for many years, the practicability of RCM measurements in patients with the clinical differential diagnosis of PV versus ET has been debated. 2 In addition, the diagnostic accuracy of different Hb or Hct threshold values as surrogate markers for RCM have been considered but no firm conclusion has ever been reached. 4, 13, [22] [23] [24] However, recent studies, irrespectively of the chosen approach, have shown that a meaningful discrimination between PV and ET may not be achieved without an adequate BM evaluation, 25 an important component of diagnostic algorithms for PV and ET diagnoses in the 2016 revised WHO classification.
5,15
Patients with JAK2-mutated ET share many molecular genetic features with PV and it has been postulated that both groups may belong to a biological continuum in which the extent of erythrocytosis is determined by physiological and genetic factors. 26 In some published series JAK2-mutated ET patients were reported to undergo transformation to PV with a cumulative risk of 29% at 15 years, while no transformation to PV was observed in CALR-mutated ET patients. 27 It was therefore suggested by these authors that JAK2-mutated ET and PV may represent different phenotypes in the evolution of a single MPN. 27 However, the total of 745 ET patients included in the mentioned study had been diagnosed between 1980 and 2012, and all diagnoses were assigned in accordance with criteria in use at the time of initial disease presentation. 28 Since the WHO diagnostic guidelines had only been applied after women is sufficient to establish the presence of erythrocytosis while a corresponding BM evaluation is necessary to establish the diagnosis of PV. 5 In conclusion, a blinded review by a central panel of six hematopathologists has validated the 2016 revised WHO classification 5 regarding the specific BM histological features which characterize PV and confirmed and extended the notion that there are no significant differences regarding BM morphology between mPV and overt stages of PV. Moreover, there was also a high rate of reproducibility regarding the discrimination between PV and ET as well as in relation to diagnosing pre-PMF and reactive conditions.
ACKNOWLEDGMENT
Supported by the Alpine Oncology Foundation (AOF).
CONFLICT OF INTEREST
Nothing to report. 
AUTHOR CONTRIBUTIONS
Conception
